[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.196.37. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 11, 2001

Pneumococcal Vaccination in Adults—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(2):166-167. doi:10.1001/jama.286.2.166

In Reply: As our analysis showed, most adults who develop IPD have a vaccine indication according to current guidelines.1 Furthermore, most IPD among adults is due to serotypes that are included in the PPV. Current vaccine recommendations also address those people most likely to die from IPD. The burden of IPD in adults remains high even though PPVs have been available for several decades.2 Improving vaccine coverage among adults with vaccine indications will reduce disease burden. As the PPV has been shown to be safe and cost effective for preventing IPD, use of the vaccine should be actively promoted.

First Page Preview View Large
First page PDF preview
First page PDF preview
×